Financials in USD. Standardized financial statements.
A compact view of how HTG Molecular Diagnostics, Inc. turns revenue into operating income and net income.
| Metric | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $6.37M | $8.91M | $8.55M | $19.20M | $21.50M | $14.76M | $5.13M | $4.04M | $3.33M | $2.24M |
| Revenue Growth? | -28.5% | +4.2% | -55.5% | -10.7% | +45.7% | +187.6% | +27.0% | +21.4% | +48.4% | 0.0% |
| Cost of Revenue? | $4.57M | $4.09M | $3.99M | $8.91M | $5.09M | $4.97M | $4.14M | $3.34M | $3.20M | $2.25M |
| Gross Profit? | $1.79M | $4.81M | $4.56M | $10.29M | $16.41M | $9.79M | $996,846 | $706,064 | $124,042 | -$3,826 |
| Gross Margin? | +28.2% | +54.0% | +53.3% | +53.6% | +76.3% | +66.3% | +19.4% | +17.5% | +3.7% | -0.2% |
| Operating Expenses? | $22.62M | $22.64M | $24.14M | $29.25M | $32.57M | $27.51M | $25.33M | $19.60M | $12.97M | $11.91M |
| Operating Income? | -$20.83M | -$17.82M | -$19.59M | -$18.96M | -$16.16M | -$17.72M | -$24.33M | -$18.89M | -$12.85M | -$11.92M |
| EBITDA? | -$20.14M | -$19.56M | -$17.96M | -$16.60M | -$14.08M | -$16.41M | -$22.69M | -$19.01M | -$12.75M | -$11.24M |
| Income Before Tax | -$21.58M | -$17.12M | -$20.86M | -$19.29M | -$16.45M | -$18.96M | -$26.03M | -$21.39M | -$13.96M | -$11.77M |
| Income Tax Expense | $10,837 | $22,475 | $14,415 | $3,379 | $3,526 | $2,921 | $10,118 | $10,189 | $0 | $0 |
| Net Income? | -$21.59M | -$17.15M | -$20.87M | -$19.30M | -$16.45M | -$18.96M | -$26.04M | -$21.40M | -$13.96M | -$11.77M |
| EPS? | $-0.24 | $-0.30 | $-0.32 | $-0.50 | $-0.75 | $-2.24 | $-4.58 | $-3.90 | $-52.33 | $-44.13 |
| Diluted EPS? | $-0.24 | $-0.30 | $-0.32 | $-0.50 | $-0.75 | $-2.24 | $-4.58 | $-3.90 | $-5.95 | $-44.13 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality